Weekly Digest – December 2025 Weekly Digest – December 2025 15 December 2025: Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer The US […]
Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: AstraZeneca Pharma India gets CDSCO nod for Datopotamab deruxtecan for treating metastatic breast cancer AstraZeneca Pharma India Ltd. announced that the Central Drugs Standard Control Organisation (CDSCO) […]
Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: DATROWAY Type II Variation Application validated in the EU as first-line treatment for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy The […]
Weekly Digest – December 2025 Weekly Digest – December 2025 18 December 2025: JSKN003 was granted Breakthrough Therapy Designation by the FDA for the treatment of PROC Alphamab Oncology announced that the U.S. FDA has granted Breakthrough Therapy Designation to JSKN003 for the treatment of adult patients with […]
Weekly Digest – December 2025 Weekly Digest – December 2025 15 December 2025: Huadong Medicine announced that HDM2012 has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for two indications: gastric cancer or gastroesophageal junction cancer and pancreatic cancer Huadong […]
Weekly Digest – December 2025 Weekly Digest – December 2025 16 December 2025: Cellectar Biosciences announces strategic supply agreement with Ionetix for Actinium-225 and Astatine-211 to advance targeted alpha therapies Cellectar Biosciences announced a multi-year strategic supply agreement with Ionetix Corporation to secure clinical and commercial-scale supplies of the alpha-emitting radioisotopes […]
